Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib with reduced chemotherapy in Ph+ ALL
NCT02611492Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nilotinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Assistance publique - Hôpitaux de Paris. Started Apr 2016; status: recruiting.
02
Drugs
nilotinib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT02611492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611492.